Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Mar 18;93(4-5):666-70.
doi: 10.1016/j.physbeh.2007.11.007. Epub 2007 Nov 12.

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties

Jack Bergman  1 , Marcus S Delatte, Carol A Paronis, Kiran Vemuri, Ganesh A Thakur, Alex Makriyannis
Affiliations
Review

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties

Jack Bergman et al. Physiol Behav. .

Abstract

The CB1 inverse agonist/antagonist SR141716A recently has been introduced for the management of obesity (rimonabant; Acomplia) and appears to have beneficial effects. However, its utility may be hampered in some individuals by adverse effects including nausea or emesis or by mood depression. The recent development of biochemically 'neutral' antagonists such as AM4113 (Sink et al., 2007) has allowed an initial evaluation of the proposition that adverse effects of SR141716A are associated with its inverse agonist activity. Thus far, data comparing SR141716A and AM4113 across several species indicate that both drugs produce dose-related direct effects on operant behavior within the same range of doses that serve to antagonize the behavioral and hypothermic effects of a CB1 agonist. However, initial observations suggest that AM4113 may not produce preclinical indications of nausea or emesis. Further studies with AM4113 and other novel CB1 antagonists differing in efficacy should amplify our understanding of the relationship between the pharmacological activity of CB1 antagonists and their behavioral effects.

PubMed Disclaimer

References

    1. Acomplia, European Public Assessment Report 2007. 2007. May 31, http://www.emea.europa.eu/humandocs/Humans/EPAR/acomplia/acomplia.htm.
    1. Janoyan JJ, Crim JL, Darmani NA. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids. Pharmacology, Biochemistry & Behavior. 2002;71:155–162. - PubMed
    1. Meschler JP, Kraichely DM, Wilken GH, Howlett AC. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3- carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)- 1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochemical Pharmacology. 2000;60:1315–1323. - PubMed
    1. Sim-Selley LJ, Martin BR. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)- tetrahydrocannabinol on cannabinoid receptor adaptation in mice. Journal of Pharmacology & Experimental Therapeutics. 2002;303:36–44. - PubMed
    1. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology. 1997;132:104–106. - PubMed

Publication types

MeSH terms